Sai Parenterals IPO Details: Date, Price, GMP, Lot Size & Review

What is the Sai Parenterals IPO?

Sai Parenterals Limited is a Hyderabad-based pharmaceutical formulations company with over two decades of operations since its founding in 2001. The company is now tapping the public markets with a ₹408.79 crore IPO, making it a notable mainboard listing in the pharma space in early 2026.

Unlike the SME IPOs we've covered recently, the Sai Parenterals IPO is a mainboard issue listing on both BSE and NSE, making it accessible to a wider category of investors with a significantly lower minimum investment threshold. The issue is structured as a combination of a fresh issue and an offer for sale (OFS), meaning proceeds will be used both for business expansion and by existing shareholders exiting their positions.

The company operates across two key business segments branded generic formulations and contract development and manufacturing (CDMO) services catering to domestic and international markets including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.

Sai Parenterals IPO Price Band & Share Price

The Sai Parenterals IPO price band is set between ₹372 and ₹392 per share, with a face value of ₹5 per share. The upper end of the price band (₹392) is the most relevant figure for allotment purposes, as most investors bid at the cut-off price.

The Sai Parenterals share price on listing day could vary above or below ₹392 depending on market sentiment, GMP trends, and overall subscription levels in the days leading up to April 2, 2026.

Sai Parenterals IPO GMP (Grey Market Premium)

The Sai Parenterals IPO GMP (Grey Market Premium) is an unofficial indicator of expected listing gains, traded outside regulated exchanges. GMP tends to fluctuate daily based on subscription demand, market conditions, and broader market sentiment.

As this IPO is currently open for subscription (March 24–27, 2026), the GMP will be actively tracked by investors. A positive and rising GMP generally signals strong listing prospects, while a flat or negative GMP suggests cautious investor sentiment.

Disclaimer: GMP is an unofficial, unregulated indicator and should not be the sole basis for your investment decision. Always evaluate the company's fundamentals before applying.

Keep checking ultra at for the latest Sai Parenterals IPO GMP updates as the subscription progresses.

About Sai Parenterals Limited

Founded in 2001 and headquartered in Hyderabad, Telangana, Sai Parenterals Limited is a full-spectrum pharmaceutical formulations company led by MD & CEO Mr. Anil Kumar Karusala. Over the past two decades, the company has evolved from an injectables-focused business into a broader pharma platform with capabilities across multiple dosage forms and therapeutic categories.

Therapeutic Areas

The company's products span a wide range of medical conditions, including:

• Cardiovascular and neuropsychiatry

• Anti-diabetic and respiratory health

• Antibiotics and gastroenterology

• Vitamins, supplements, analgesics, and dermatology

Dosage Forms

Products are manufactured in diverse formats injectables, tablets, capsules, liquid orals, and ointments — giving the company broad market reach across hospitals, government agencies, and retail channels.

Manufacturing Facilities

Sai Parenterals operates five manufacturing facilities in India, with combined installed capacity of 1,160 million units per year on a single-shift basis:

• Unit I — GMP certified

• Unit II — WHO-GMP certified

• Unit III — TGA Australia (PIC/S) accredited

• Unit IV — WHO-GMP certified and PIC/S accredited

• Revat Laboratories (Ongole, AP) subsidiary facility

Four facilities are located in Hyderabad, Telangana, and one in Ongole, Andhra Pradesh through its subsidiary Revat Laboratories.

CDMO & International Business

The company has built a growing CDMO (Contract Development and Manufacturing Organisation) platform, supplying branded generic formulations to 10 countries through a network of 7 distributors. Export markets include Australia, New Zealand, Southeast Asia, the Middle East, and Africa. As of December 31, 2025, the company had developed 55 dossiers in-house through its R&D facility at Unit III, staffed by 34 dedicated personnel.

The company has also pursued an acquisition-led growth strategy, acquiring Units III and IV, Revat Laboratories, and a 74.60% stake in Noumed Pharmaceuticals (Australia) expanding its CDMO capabilities, regulatory reach, and international presence.

Competitive Strengths

• Expanded Product Portfolio: Evolved from an injectables-only business to a full-spectrum pharma company covering tablets, capsules, liquid orals, and ointments across multiple therapeutic categories.

• Dual Business Model: Operates across both branded generic formulations and CDMO services, providing revenue diversification and exposure to the high-growth outsourced manufacturing segment.

• Multi-facility Manufacturing Base: Five facilities with combined capacity of 1,160 million units/year, holding international regulatory accreditations including TGA Australia and PIC/S.

• In-house R&D Capability: A dedicated FR&D team of 34 personnel and 55 dossiers developed in-house, supporting a growing product pipeline.

• Institutional Distribution Reach: Supplies to government procurement agencies, PMBJP, ESI hospitals, and super stockists in India.

• Growing Export Presence: Products supplied to 10 countries through 7 international distributors, with regulatory approvals supporting access to regulated markets.

Key Risks to Consider

Before investing in the Sai Parenterals IPO, carefully evaluate these risk factors:

• Geographic Concentration: All five manufacturing facilities are in Telangana and Andhra Pradesh, making the company vulnerable to regional disruptions.

• Dependence on Injectables: Injectable formulations have historically contributed the majority of revenue; any regulatory or demand-side disruption in this category could materially hurt financials.

• Customer Concentration: Top 10 branded generics customers contributed over 66% of segment revenue in the six months ended September 2025.

• Supplier Concentration: Top 5 suppliers accounted for ~56.68% of total raw material purchases in the same period.

• Negative Operating Cash Flows: The company reported negative operating cash flows of ₹66.01 Cr in the first half of FY26, raising short-term liquidity concerns.

• Past Regulatory Action: Subsidiary Revat Laboratories was directed to cease manufacturing in May 2024 for alleged Schedule M non-compliance, though the order was subsequently stayed by the High Court.

• Government Tender Dependence: A portion of revenue relies on state government procurement tenders; any blacklisting or procurement policy changes could hurt revenues.

• Acquisition Integration Risk: The recent acquisitions of Revat Laboratories and Noumed carry integration and financial risks.

Should You Apply for the Sai Parenterals IPO?

The Sai Parenterals Limited IPO brings a compelling combination of factors: a 25-year operating history, strong revenue growth, international regulatory accreditations, a growing CDMO business, and one of the lowest minimum retail investments in recent IPO history at just ~₹14,896 per lot.

The use of IPO proceeds particularly the ₹110.8 Cr earmarked for capacity expansion — signals the company's ambition to meaningfully scale up post-listing. The investment in Noumed Pharmaceuticals (Australia) adds an interesting international growth dimension.

That said, the significant negative operating cash flows (–₹66 Cr in just six months), geographic concentration of manufacturing facilities, dependence on a limited customer and supplier base, and the past regulatory action at Revat Laboratories are material risks that investors must weigh carefully.

For investors looking for affordable pharma exposure with a long-term growth story, the low lot size makes this IPO worth considering. However, the risk profile warrants caution, and conservative investors may prefer to watch the listing day performance before making a decision.

Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Please consult a registered financial advisor before making investment decisions. Investments in IPOs are subject to market risks.